Cellular Biomedicine
Cellular Biomedicine Group develops proprietary cell therapies for the treatment of cancer and degenerative diseases.
The company conducts immuno-oncology and stem cell clinical trials in China using products from its integrated GMP laboratory.
In September 2018, Cellular Biomedicine entered into a strategic licensing and collaboration agreement with Swiss pharma giant Novartis to manufacture and supply the CAR-T cell therapy Kymriah (tisagenlecleucel) in China. Novartis will be the exclusive holder of the marketing license.
Latest Cellular Biomedicine News & Features
27 September 2018
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze